

Date: 11th December, 2025

To,
BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai — 400 001.

Ref.: BSE Scrip Code - 539730**Subject: Intimation of Schedule of 'Value Discovery Summit', under the SEBI (Listing Obligations and Disclosure Requirement), Regulation 2015**

Dear Sir / Madam,

Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosures Requirements), Regulation, 2015, ("the Listing Regulations"), we hereby apprise that the management of the Company will be interacting with Investors/ Analysts as per the following schedule (hereinafter referred to as "Virtual Meeting"):

Date	Time	Name of Meeting	Meeting Type	Scheduled For
December 16, 2025	11:30 A.M. (IST)	Beyond the Numbers – Value Discovery Summit-2025	Virtual- Meeting	Group Meet

Discussions will be based on publicly available information. No unpublished price-sensitive information (UPSI) is intended to be discussed during the interactions.

This information is submitted to you pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Kindly note that changes may happen due to exigencies on the part of Host / Company.

Kindly oblige and take the same on your Records.

Thanking you,
Yours faithfully,
For Fredun Pharmaceuticals Limited

Fredun Medhora
Managing Director
DIN: 01745348



BeyondThe Numbers

Value Discovery Summit

2025

Powered By



Co-Powered By



Fredun Pharmaceuticals Limited

Tuesday, 16th December,
11:30 AM

[Registration Link](#)

RSVP:

Mr. Shashank Mahajan

Director

+91 87790 64899

value.educator@gmail.com

www.valueeducator.com

RSVP:

Ms. Tejas Vaity

Investor Relations Executive

+9188285 59362

tejas@kirinadvisors.com

www.kirinadvisors.com

Disclaimer:

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment with RAASB and certification from NISM in no way guarantee performance of the Research Analyst or provide any assurance of returns to investors.